Abstract Library

#4633 Mini invasive pancreatectomy for pancreatic neuroendocrine tumours: Current state of management in France

Introduction: Pancreatic neuroendocrine tumours (NETs) accounts for 2% of pancreatic tumours and their management is challenging. Surgery is the most radical treatment, but for small lesions, parenchyma sparing techniques are also used.

Conference:

Presenting Author: Muzzolini M

Authors: Muzzolini M, de Ponthaud C, Gaujoux S,

Keywords: laparoscopic NETs surgical outcomes,

#4366 Care of neuroendocrine tumours: The Collaborative of sUrgical Teams for NeuroEndocrine Tumors (CUTNETs)

Introduction: Despite the importance of surgical management, most data on NETs surgical care come from single-centre studies, limiting generalisability. To address these challenges and improve NETs surgical care, a worldwide Collaborative of Surgical Teams for NeuroEndocrine Tumors (CUTNETs) was created.

Conference:

Presenting Author: Hallet J

Authors: Hallet J, Shapiro J, Pascher A, Gaujoux S, Gangi A,

Keywords: surgery, carcinoid, neuroendocrine,

#3726 Inflammation based index and tumor heterogeneity on pretherapeutic 68Ga DOTATOC PET/CT predict outcome in midgut neuroendocrine tumor patients treated with 177Lu-oxodotreotide

Introduction: Peptide receptor radionuclide therapy with 177Lu oxodotreotide (LuPRRT) is a standard treatment for the management of patients with inoperable metastatic well-differentiated neuroendocrine tumors of the midgut (iNET). As LuPRRT becomes widely used for a heterogeneous population of NET patients, practical predictive biomarkers are needed. Inflammation based index (IBI) derived from serum C reactive protein and albumin is associated with progression free survival (PFS) and overall survival (OS) in patients with PRRT for NETs. Ga-68 DOTATOC PET/CT (DOTAPET) assessment of lesion heterogeneity was predictive for response to PRRT.

Conference:

Presenting Author: Vija L

Authors: Vija L, Dierickx L, Kanoun S, Texier J, Terroir M,

Keywords: LuPRRT, GaDOTA PET/CT, neuroendocrine tumor, outcome,

#3467 Correlation study between 68Ga-DOTATOC PET/CT metrics and 177Lu-DOTATATE dosimetry for non-pancreatic neuroendocrine tumors

Introduction: 177Lu-DOTATATE therapy is validated for the management of well-differentiated metastatic, somatostatin receptor expressing non-pancreatic neuroendocrine tumors (npNETs). The evaluation of the tissue absorbed dose (D) could allow to assess the risk-benefit ratio of PRRT. Unfortunately, due its complexity, dosimetry study is hardly performed in routine.

Conference:

Presenting Author:

Authors: Texier J, Jocmek M, Dierickx L, Vallot D, Brillouet S,

Keywords: 68Ga-DOTATOC PET/CT, non-pancreatic neuroendocrine tumor, 177Lu-DOTATATE, dosimetry,

#3442 Surgical management of patients with sporadic Zollinger-Ellison Syndrome: An ACHBT and GTE study

Introduction: The only curative treatment of sporadic gastrinoma is complete surgical resection, but its surgical management remain controversial.

Conference:

Presenting Author: Gaujoux S

Authors: Gaujoux S, Robin L, Sauvanet A, Walter T, Naja H,

Keywords: gastrinoma, surgery, pancreaticoduodenectomy, lymphadenectomy,